Allosteric regulation

Allosteric regulation

In biochemistry, allosteric regulation is the regulation of an enzyme or other protein by binding an effector molecule at the protein's allosteric site (that is, a site other than the protein's active site). Effectors that enhance the protein's activity are referred to as "allosteric activators", whereas those that decrease the protein's activity are called "allosteric inhibitors". The term "allostery" comes from the Greek "allos", "other," and "stere", "space," referring to the regulatory site of an allosteric protein's being separate from its active site. Allosteric regulations are natural example of control loops, such as feedback from downstream products or feedforward from upstream substrates.

Models of allosteric regulation

Most allosteric effects can be explained by the "concerted" MWC model put forth by Monod, Wyman, and Changeux, [J. Monod, J. Wyman, J.P. Changeux. (1965). On the nature of allosteric transitions:A plausible model. "J. Mol. Biol.", May;12:88-118.] or by the sequential model described by Koshland, Nemethy, and Filmer. [D.E. Jr Koshland, G. Némethy, D. Filmer (1966) Comparison of experimental binding data and theoretical models in proteins containing subunits. "Biochemistry". Jan;5(1):365-8] Both postulate that enzyme subunits exist in one of two conformations, tensed (T) or relaxed (R), and that relaxed subunits bind substrate more readily than those in the tense state. The two models differ most in their assumptions about subunit interaction and the preexistence of both states.

Concerted model

The concerted model of allostery, also referred to as the symmetry model or MWC model, postulates that enzyme subunits are connected in such a way that a conformational change in one subunit is necessarily conferred to all other subunits. Thus all subunits must exist in the same conformation. The model further holds that in the absence of any ligand (substrate or otherwise), the equilibrium favors one of the conformational states, T or R. The equilibrium can be shifted to the R or T state through the binding of one ligand (the allosteric effector or ligand) to a site that is different from the active site (the allosteric site).

Sequential model

The sequential model of allosteric regulation holds that subunits are not connected in such a way that a conformational change in one induces a similar change in the others. Thus, all enzyme subunits do not necessitate the same conformation. Moreover, the sequential model dictates that molecules of substrate bind via an induced fit protocol. In general, when a subunit randomly collides with a molecule of substrate, the active site essentially forms a glove around its substrate. While such an induced fit converts a subunit from the tensed state to relaxed state, it does not propagate the conformational change to adjacent subunits. Instead, substrate-binding at one subunit only slightly alters the structure of other subunits so that their binding sites are more receptive to substrate. To summarize:
* subunits need not exist in the same conformation
* molecules of substrate bind via induced-fit protocol
* conformational changes are not propagated to all subunits
* substrate-binding causes increased substrate affinity in adjacent subunits

Allosteric activation and inhibition


"Allosteric activation", such as the binding of oxygen molecules to hemoglobin, occurs when the binding of one ligand enhances the attraction between substrate molecules and other binding sites. With respect to hemoglobin, oxygen is effectively both the substrate and the effector. The allosteric, or "other," site is the active site of an adjoining protein subunit. The binding of oxygen to one subunit induces a conformational change in that subunit that interacts with the remaining active sites to enhance their oxygen affinity.


"Allosteric inhibition" occurs when the binding of one ligand decreases the affinity for substrate at other active sites. For example, when 2,3-BPG binds to an allosteric site on hemoglobin, the affinity for oxygen of all subunits decreases. []

Another good example is strychnine, a convulsant poison, acting as an allosteric inhibitor of glycine. Glycine is a major post-synaptic inhibitory neurotransmitter in mammalian spinal cord and brain stem. Strychnine acts at a separate binding site on the glycine receptor in an allosteric manner; i.e. its binding lowers the affinity of the glycine receptor for glycine. Strychnine thus inhibits the action of an inhibitory transmitter, causing convulsions.

Types of effectors

Many allosteric proteins are regulated by their substrate; such a substrate is considered a "homotropic allosteric modulator", and is typically an activator. Non-substrate regulatory molecules are called "heterotropic allosteric modulators" and can be either activators or inhibitors.

Some allosteric proteins can be regulated by their substrates and by other molecules, as well. Such proteins are capable of both homotropic and heterotropic interactions.


Allosteric modulation of a receptor results from the binding of allosteric modulators at a different site (regulatory site) other than of the endogenous ligand (orthosteric ligand) and enhances or inhibits the effects of the endogenous ligand. It normally acts by causing a conformational change in a receptor molecule which results in a change in the binding affinity of the ligand. In this way an allosteric ligand “modulates” its activation by a primary “ligand” and can be thought to act like a dimmer switch in an electrical circuit, adjusting the intensity of the receptor’s activation.

The anti-anxiety drugs Valium, Xanax, Librium and Ativan, for example, “potentiates” or turn up the activity of the neurotransmitter gamma-aminobutyric acid (GABA) when it binds to its primary ligand, the benzodiazepine receptor. More recent examples of drugs which allosterically modulate their drug targets include Cinacalcet and Maraviroc

Allosteric sites as drug targets

Allosteric sites may represent a novel .There are a number of advantages in using allosteric modulators as preferred therapeutic agents over classic orthosteric ligands. For example, GPCR allosteric binding sites have not faced the same evolutionary pressure as orthosteric sites to accommodate an endogenous ligand so are more diverse.A. Christopoulos, L.T. May, V.A. Avlani and P.M. Sexton (2004) G-protein-coupled receptor allosterism:the promise and the problem(s). "Biochemical Society Transactions" Volume 32, part 5 ] Therefore greater GPCR selectivity may be obtained by targeting allosteric sites.This is particularly useful for GPCRs where selective orthosteric therapy has been difficult because of sequence conservation of the orthosteric site across receptor subtypes. L.T. May , K. Leach, P.M. Sexton, and A. Christopoulos. (2007). Allosteric Modulation of GProtein–Coupled Receptors "Annu. Rev. Pharmacol. Toxicol." 47:1–51 ] Also these modulators is a decreased potential for toxic effects, since modulators with limited co-operativity will have a ceiling level to their effect, irrespective of the administered dose. Another type of pharmacological selectivity that is unique to allosteric modulators is based on cooperativity. An allosteric modulator may display neutral cooperativity with an orthosteric ligand at all subtypes of a given receptor except the subtype of interest, which is termed absolute subtype selectivity. If an allosteric modulator does not possess appreciable efficacy, it can provide another powerful therapeutic advantage over orthosteric ligands, namely, the ability to selectively tune up or down tissue responses only when the endogenous agonist is present.

Homotropic allosteric interaction

A "homotropic allosteric interaction" is one in which the activity of an allosteric protein is regulated by its substrate. Homotropic modulators tend to be allosteric activators; that is, they typically up-regulate the activity of the protein. They can do so by inducing the comfomational change of the multi-subunit allosteric protein from the inactive state (Tense state) to the active state (Relaxed state). Homotropic effects are in contrast to heterotropic effects in which the allosteric modulator is something other than the protein's substrate.

Heterotropic allosteric modulator

A "heterotropic allosteric interaction" is one in which the activity of an allosteric protein is regulated by a molecule other than the protein's substrate. Heterotropic effects are in contrast to homotropic effects in which the allosteric protein is regulated by its substrate.

See also

* Cooperative binding
* Enzyme kinetics


Wikimedia Foundation. 2010.

Игры ⚽ Нужен реферат?

Look at other dictionaries:

  • allosteric regulation — A catalysis regulating process in which the binding of a small effector molecule to one site on an enzyme affects the activity at another site …   Glossary of Biotechnology

  • allosteric control — See: allosteric regulation …   Glossary of Biotechnology

  • allosteric — allosterically, adv. /al euh ster ik, stear /, adj. Biochem. pertaining to regulation of the rate of an enzymatic process. [1960 65; ALLO + STERIC] * * * …   Universalium

  • Negative allosteric modulator — A negative allosteric modulator (NAM) is a drug which decreases the activity of a receptor indirectly via disactivation of an allosteric site on the protein. NAMs are similar to inverse agonists in that they conteract overall receptor activation …   Wikipedia

  • negative regulation — Negative feedback in biological systems mediated by allosteric regulatory enzymes …   Dictionary of molecular biology

  • Enzyme — Biocatalyst redirects here. For the use of natural catalysts in organic chemistry, see Biocatalysis. Human glyoxalase I. Two zinc ions that are needed for the enzyme to catalyze its reaction are shown as purp …   Wikipedia

  • Morpheein — Proteins that function as morpheeins are illustrated using a dice analogy where one die can morph to two different shapes, cubic and tetrahedral. The illustrated assemblies apply a rule that the die face with one spot must contact the die face… …   Wikipedia

  • Ribonucleotide reductase — protein Name = ribonucleotide reductase M1 polypeptide caption = width = HGNCid = 10451 Symbol = RRM1 AltSymbols = EntrezGene = 6240 OMIM = 180410 RefSeq = NM 001033 UniProt = P23921 PDB = ECnumber = Chromosome = 11 Arm = p Band = 15.5… …   Wikipedia

  • Glutamate dehydrogenase 1 — GLUD1 (Glutamate dehydrogenase 1) is a mitochondrial matrix enzyme, with a key role in the nitrogen and glutamate (Glu) metabolism and the energy homeostasis. GLUD1 is expressed at high levels in liver, brain, pancreas and kidney, but not in… …   Wikipedia

  • Enzyme inhibitor — Enzyme inhibitors are molecules that bind to enzymes and decrease their activity. Since blocking an enzyme s activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. They are also used as herbicides and… …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”